NCT03038646View on ClinicalTrials.gov

A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

April 20, 2017

Study Completion Date

April 20, 2017

Conditions
Healthy Subjects
Interventions
DRUG

MIN-101

Trial Locations (1)

BT2 7BA

Biokinetic Europe, Belfast

Sponsors
All Listed Sponsors
lead

Minerva Neurosciences

INDUSTRY